FIELD: biotechnology.
SUBSTANCE: fusion proteins are proposed to induce a specific immune response against Mycobacterium tuberculosis, including Ag85B proteins, Tb10.4 M.tuberculosis, fragments of flagellin FliC S.Typhimurium, connected by flexible bridges, encoding polynucleotides, genetic constructs for expression of polynucleotides, recombinant cells, and vaccine options for tuberculosis prevention or treatment based on the described fusion protein, vaccine is developed for humans or animals. The proposed vaccine has an efficiency exceeds that of BCG.
EFFECT: security and simplicity in production and application.
8 cl, 4 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HYBRID PROTEIN-BASED POLYVALENT INFLUENZA VACCINE | 2013 |
|
RU2531235C2 |
| HYBRID PROTEIN VACCINE AGAINST PNEUMONIA CAUSED BY Streptococcus pneumoniae | 2012 |
|
RU2510281C2 |
| ANALGETIC AGENT ON THE BASIS OF PLASMID DNA CODING HNP-1, OR HNP-2, OR HNP-3 (VERSIONS) | 2014 |
|
RU2597789C2 |
| VACCINE FOR PREVENTION AND TREATMENT OF ROTAVIRAL INFECTION CONTAINING HYBRID PROTEIN AS ACTIVE AGENT (VERSIONS) | 2013 |
|
RU2539913C2 |
| VACCINE FOR THE PREVENTION OR TREATMENT OF CORONAVIRUS INFECTION BASED ON A GENETIC CONSTRUCT | 2020 |
|
RU2747762C1 |
| VACCINE AGAINST TUBERCULOSIS | 2017 |
|
RU2647831C1 |
| HUMANIZED MONOCLONAL ANTIBODY SPECIFIC TO SYNDECAN-1 | 2015 |
|
RU2611685C2 |
| METHOD FOR OBTAINING RECOMBINANT HUMAN OREXIN A , PLASMID DNA, STRAIN PRODUCER | 2016 |
|
RU2647771C2 |
| HUMANISED MONOCLONAL ANTIBODY SPECIFIC TO SYNDECAN-1 | 2013 |
|
RU2551235C2 |
| HYBRID PROTEIN IGF-1-LONG FOR TREATING STROKE, NUCLEIC ACID, VECTOR, CELL, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT | 2018 |
|
RU2711111C1 |
